Research Topics
| Gordon K WilcockSummaryAffiliation: University of Oxford Country: UK Publications
| Collaborators
|
Detail Information
Publications
Replication by the Epistasis Project of the interaction between the genes for IL-6 and IL-10 in the risk of Alzheimer's diseaseOnofre Combarros
Neurology Service and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Marqués de Valdecilla University Hospital University of Cantabria, 39008 Santander, Spain
J Neuroinflammation 6:22. 2009....- The dopamine β-hydroxylase -1021C/T polymorphism is associated with the risk of Alzheimer's disease in the Epistasis ProjectOnofre Combarros
Neurology Service and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Marqués de Valdecilla University Hospital University of Cantabria, 39008 Santander, Spain
BMC Med Genet 11:162. 2010..We therefore examined the associations with AD of the DBH -1021T allele and of the above interactions in the Epistasis Project, with 1757 cases of AD and 6294 elderly controls... - Non-linear relationships of cerebrospinal fluid biomarker levels with cognitive function: an observational studyJonathan H Williams
OPTIMA, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, UK
Alzheimers Res Ther 3:5. 2011..Levels of cerebrospinal fluid (CSF) β-amyloid (Aβ) and Tau proteins change in Alzheimer's disease (AD). We tested if the relationships of these biomarkers with cognitive impairment are linear or non-linear... 
Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trialGordon K Wilcock
University of Oxford, John Radcliffe Hospital, Oxford, UK
Lancet Neurol 7:483-93. 2008..We aimed to test the effects of tarenflurbil, a selective Abeta(42)-lowering agent (SALA), on cognition and function in patients with mild to moderate AD...
Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studiesGordon K Wilcock
From the Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Headington, UK
J Clin Psychiatry 69:341-8. 2008..The current retrospective analysis evaluated the efficacy and safety of memantine in a subpopulation of patients with Alzheimer's disease exhibiting behavioral symptoms of agitation/aggression or psychosis at baseline...- Retrospective evaluation of revised criteria for the diagnosis of Alzheimer's disease using a cohort with post-mortem diagnosisCeleste A de Jager
Department of Physiology, Anatomy and Genetics, University of Oxford, UK
Int J Geriatr Psychiatry 25:988-97. 2010..We aimed to evaluate the new predementia-AD criteria through their retrospective application to the OPTIMA cohort with post-mortem (PM) confirmed diagnoses... - Galantamine in Alzheimer's diseaseGeorge Razay
University of Oxford, Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Headington, Oxford, UK
Expert Rev Neurother 8:9-17. 2008..The magnitude of the treatment effect is similar to that of other cholinesterase inhibitors. Adverse events experienced by patients treated with galantamine are usually mild, gastrointestinal and may improve with dose reduction... - Predicting the time of conversion to MCI in the elderly: role of verbal expression and learningAbderrahim Oulhaj
OPTIMA, Level 4, John Radcliffe Hospital, Oxford OX3 9DU, UK
Neurology 73:1436-42. 2009..We aimed to develop a way of predicting the period of time before cognitive impairment occurs in community-dwelling elderly. The method is illustrated by the use of simple tests of different cognitive domains... - Specific AD impairment in concurrent performance of two memory tasksSarah E MacPherson
Human Cognitive Neuroscience, Department of Psychology, University of Edinburgh, Edinburgh, UK
Cortex 43:858-65. 2007.... - Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?Patrick G Kehoe
Dementia Research Group, Institute of Clinical Neurosciences, Department of Clinical Science at North Bristol, University of Bristol, Frenchay Hospital, Frenchay, Bristol
Lancet Neurol 6:373-8. 2007.... - Protein and gene expression of tumour necrosis factor receptors I and II and their promoter gene polymorphisms in Alzheimer's diseaseDoris Culpan
Dementia Research Group, Institute of Clinical Neurosciences, Department of Clinical Sciences at North Bristol, University of Bristol, Frenchay Hospital, Frenchay, Bristol, United Kingdom
Exp Gerontol 42:538-44. 2007..Our findings suggest that TNF-RI and -RII promoter gene polymorphisms and variations in protein and gene expression of these receptors are unlikely to play a major role in the development of AD... - Neither sequence variation in the IL-10 gene promoter nor presence of IL-10 protein in the cerebral cortex is associated with Alzheimer's diseaseDoris Culpan
Dementia Research Group, Institute of Clinical Neurosciences, Department of Clinical Sciences at North Bristol, University of Bristol, John James Buildings, Frenchay Hospital, Frenchay, Bristol, BS16 1LE, United Kingdom
Neurosci Lett 408:141-5. 2006..Levels of IL-10 protein and gene expression examined also did not appear to be related to AD. Despite this being a relatively small sample, these data suggest that IL-10 does not play a major role in the development of AD... - Loss of perineuronal net N-acetylgalactosamine in Alzheimer's diseaseShabnam Baig
Department of Clinical Science at North Bristol, Care of the Elderly, Frenchay Hospital, University of Bristol, Bristol, UK
Acta Neuropathol 110:393-401. 2005..This could in turn lead to increased activity of the glutamatergic and other neurons onto which they synapse... - Premorbid effects of APOE on synaptic proteins in human temporal neocortexSeth Love
Department of Neuropathology, University of Bristol Institute of Clinical Neurosciences, Frenchay Hospital, Bristol BS16 1LE, UK
Neurobiol Aging 27:797-803. 2006..01). APOE influences the concentration of synaptic proteins in normal superior temporal cortex and may thereby affect the response to injury, and the risk and outcome of a range of neurologic diseases... - Sequence variants of IDE are associated with the extent of beta-amyloid deposition in the Alzheimer's disease brainMia E L Blomqvist
Center for Genomics and Bioinformatics, Karolinska Institute, Stockholm, Sweden
Neurobiol Aging 26:795-802. 2005..Results indicate that alleles of IDE contribute to variability in A beta deposition in the AD brain and suggest that this relationship may have relevance for the degree of cognitive dysfunction in AD patients... - Productive herpes simplex virus in brain of elderly normal subjects and Alzheimer's disease patientsMatthew A Wozniak
Molecular Neurobiology Laboratory, Faculty of Life Sciences, The University of Manchester, Manchester, United Kingdom
J Med Virol 75:300-6. 2005..The HSV1 results confirm the original PCR findings that show the presence of HSV1 DNA sequences in many elderly brains, and indicate also that the whole functional HSV1 genome is present, and that the virus has replicated... - alpha- and beta-secretase: profound changes in Alzheimer's diseaseSusan J Tyler
Molecular Neurobiology Unit, URCN Care of the Elderly University of Bristol, Bristol Royal Infirmary, Bristol, UK
Biochem Biophys Res Commun 299:373-6. 2002..Eighty percent of Alzheimer brains examined had an increase in beta-secretase, a decrease in alpha-secretase, or both; which may account for the means by which the majority of people develop Alzheimer's disease... - Patterns of clinically detectable treatment effects with galantamine: a qualitative analysisChristine Joffres
Geriatric Medicine Research Unit, Queen Elizabeth II Health Sciences Centre, Halifax, Canada
Dement Geriatr Cogn Disord 15:26-33. 2003..Clinicians appear to be skeptical of cognitive changes not supported by like changes in function or behaviour... - Haplotypes extending across ACE are associated with Alzheimer's diseasePatrick G Kehoe
Department of Care of the Elderly, University of Bristol, The John James Building, Frenchay Hospital, Bristol, UK
Hum Mol Genet 12:859-67. 2003..Results support a model whereby decreased ACE activity may influence AD susceptibility by a mechanism involving beta-amyloid metabolism... - Memantine for the treatment of dementiaGordon K Wilcock
Department of Care of the Elderly, University of Bristol, UK
Lancet Neurol 2:503-5. 2003..The efficacy of memantine in vascular dementia also requires further investigation... - Absence of Chlamydia pneumoniae in brain of vascular dementia patientsMatthew A Wozniak
Department of Optometry and Neuroscience, Molecular Neurobiology Laboratory, University of Manchester Institute of Science and Technology, Manchester M60 1QD, UK
Neurobiol Aging 24:761-5. 2003..025 IFU. Our results do not support a role for Cpn in the aetiology of VaD, either in the 83% of patients in whose brains we detected CMV, or in the remaining 17% without CMV in brain... - Tumour necrosis factor-alpha gene polymorphisms and Alzheimer's diseaseDoris Culpan
Department of Care of the Elderly, University of Bristol, John James Buildings, Frenchay Hospital, Frenchay, Bristol, BS16 1LE, UK
Neurosci Lett 350:61-5. 2003..014, Fisher's exact test) suggesting that the 2-1-2 haplotype may be protective against AD... - The effects of galantamine treatment on caregiver time in Alzheimer's diseaseMary Sano
Mount Sinai School of Medicine Veterans Affairs Hospital, Bronx, NY 10468, USA
Int J Geriatr Psychiatry 18:942-50. 2003..The aim of the study was to determine whether the clinical benefits of galantamine for patients with Alzheimer's disease lead to benefits for caregivers... - Common variants of ACE contribute to variable age-at-onset of Alzheimer's diseasePatrick G Kehoe
Department of Care of the Elderly, The John James Building, Frenchay Hospital, University of Bristol, UK
Hum Genet 114:478-83. 2004..These results provide an important complement to existing AD risk data, confirming that ACE harbors sequence variants that contribute to aspects of AD pathology... - Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to beta-amyloid metabolismHagit Katzov
Center for Genomics and Bioinformatics, Karolinska Institute, Stockholm, Sweden
Hum Mutat 23:358-67. 2004..Results indicate that variants of ABCA1 may affect the risk of AD, providing further support for a genetic link between AD and cholesterol metabolism... - APOE promoter, ACE1 and CYP46 polymorphisms and beta-amyloid in Alzheimer's diseaseKaty A Chalmers
University of Bristol, Department of Care of the Elderly, Frenchay Hospital, Bristol BS16 1LE, UK
Neuroreport 15:95-8. 2004..Here we report that polymorphisms within the APOE promoter, ACE1 and CYP46 gene are not risk factors for AD and are not associated with parenchymal or vascular accumulation of Abeta... - Clinical utility of computed tomography in the assessment of dementia: a memory clinic studyKelly A Condefer
Department of Neurology, The Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA
Int J Geriatr Psychiatry 19:414-21. 2004..To define the influence of computed tomography (CT) on clinical decision-making in the outpatient evaluation of dementia... - Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trialsAnne Whitehead
The University of Reading, Medical and Pharmaceutical Statistics Research Unit, Reading, UK
Int J Geriatr Psychiatry 19:624-33. 2004..The objective was to evaluate the efficacy and tolerability of donepezil (5 and 10 mg/day) compared with placebo in alleviating manifestations of mild to moderate Alzheimer's disease (AD)... - Herpesviruses in brain and Alzheimer's diseaseWoan-Ru Lin
Department of Optometry and Neuroscience, UMIST, Manchester, UK
J Pathol 197:395-402. 2002....